Lumosa Therapeutics Co. Ltd.
Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan, Asia, the Americas, and Europe. The company offers Naldebain (LT " 1001), an analgesic injection for severe pain relief after surgery. It is developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; L… Read more
Lumosa Therapeutics Co. Ltd. (6535) - Total Liabilities
Latest total liabilities as of December 2025: NT$131.04 Million TWD
Based on the latest financial reports, Lumosa Therapeutics Co. Ltd. (6535) has total liabilities worth NT$131.04 Million TWD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Lumosa Therapeutics Co. Ltd. - Total Liabilities Trend (2019–2025)
This chart illustrates how Lumosa Therapeutics Co. Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Lumosa Therapeutics Co. Ltd. Competitors by Total Liabilities
The table below lists competitors of Lumosa Therapeutics Co. Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Henan Jindan Lactic Acid Technology
SHE:300829
|
China | CN¥1.12 Billion |
|
Doman Building Materials Group Ltd
PINK:CWXZF
|
USA | $895.87 Million |
|
SSAW Hotels & Resorts Group Co.Ltd.
SHE:301073
|
China | CN¥1.49 Billion |
|
Vontron Technology Co Ltd
SHE:000920
|
China | CN¥667.94 Million |
|
Xinyaqiang Silicon Chemistry Co Ltd
SHG:603155
|
China | CN¥185.02 Million |
|
Elec-Tech International Co Ltd
SHE:002005
|
China | CN¥770.56 Million |
|
Inner Mongolia North Hauler Joint Stock Co Ltd
SHG:600262
|
China | CN¥3.27 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Lumosa Therapeutics Co. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lumosa Therapeutics Co. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lumosa Therapeutics Co. Ltd. (2019–2025)
The table below shows the annual total liabilities of Lumosa Therapeutics Co. Ltd. from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$131.04 Million | -36.22% |
| 2024-12-31 | NT$205.46 Million | -9.77% |
| 2023-12-31 | NT$227.69 Million | +5.55% |
| 2022-12-31 | NT$215.72 Million | -6.25% |
| 2021-12-31 | NT$230.11 Million | +14.13% |
| 2020-12-31 | NT$201.63 Million | -27.59% |
| 2019-12-31 | NT$278.44 Million | -- |